Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Inclusion Criteria

• •1. Age Patients must be ≥1 and ≤ 21 years of age when originally diagnosed with ALL or AML.
• •2. Diagnosis
• •1. Patients must have previously histologically confirmed ALL or AML at original diagnosis or previous relapse. Patients with treatment-related AML are eligible.
• •2. Patients must be in complete remission (CR) with less than 5% blasts in the bone marrow.
• •* Post-HSCT patients should be in first or greater CR
• •* Patients who have never received HSCT should be in second or greater CR
• •3. Patient must have detectable MRD (≥0.01%) by flow cytometry.
• •3. Performance Level Karnofsky ≥ 50% for patients \>16 years of age and Lansky ≥ 50% for patients ≤16 years of age.
• •4. Prior Therapy
• •1. Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy.
• •2. At least 14 days must have elapsed since any treatment with systemic chemotherapy including high-dose steroid (prednisone\>0.5 mg/kg or equivalent), radiotherapy, biological therapy or any other investigational therapy. (Note: low-dose steroid; prednisone ≤0.5 mg/kg/day or equivalent is allowed.)
• •3. At least 28 days must have elapsed since any cellular therapies such as chimeric antigen receptor-modified T cells.
• •4. Patients who have never had HSCT must not be a suitable candidate for HSCT. For this protocol, a suitable candidate is defined as one who has an identified donor with plans to undergo transplant within the next 28 days.
• •5. Previous HSCT:
• •* Patients having received HSCT are eligible and 60 days must have elapsed since stem cell infusion.
• •* Patients having received donor lymphocyte infusions (DLI) are eligible.
• •* At least 28 days must have elapsed from the last DLI.
• •* Must have ≥90% donor chimerism. The test for donor chimerism must have been done within the last 60 days. If patient has subsequently relapsed after HSCT but prior to enrollment on this study, the donor chimerism test is not needed.
• •* Patients must have been off all immune suppression drugs for 7 days before study entry. (at least 2 weeks for high-dose steroid, i.e. prednisone\>0.5 mg/kg or equivalent; see 4b above) (Note; low-dose steroid; prednisone ≤0.5 mg/kg/day or equivalent is allowed.)
• •5. Renal and Hepatic Function
• •1. Patients must have a serum creatinine that is less than or equal to 1.5 x the institutional upper limit of normal according to age. (Grade 1 per the CTCAE 4.0)
• •2. Patient's ALT and AST must be less than or equal to 3 x institutional upper limit of normal. (Grade 1 per the CTCAE 4.0)
• •3. Patient's total bilirubin must be less than or equal to 1.5 x institutional upper limit of normal. (Grade 1 per the CTCAE 4.0)
• •6. Cardiac Function Patient must have a shortening fraction \> 27% by ECHO or an ejection fraction \> 45% by MUGA.
• •7. Reproductive Function
• •1. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
• •2. Female patients with infants must agree not to breastfeed their infants while on this study.
• •3. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.
• •8. Hematological Function Patients must have an absolute neutrophil count \> 750/dL, platelets \> 75,000/dL AND absolute lymphocyte count \> 200/uL which is not decreasing. Patients with previous HSCT may have a platelet count \> 50,000/dL.